Stamford, CT -- (SBWIRE) -- 09/27/2013 -- OTC Stock Picks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: Soligenix Inc (OTCBB:SNGX), Elite Pharmaceuticals Inc (OTCBB:ELTP), THEDIRECTORY.COM INC (OTCMKTS:SEEK), Cannabis Science Inc (OTCMKTS:CBIS)
Soligenix Inc (OTCBB:SNGX) experienced a plunge of -2.09%, to a market valuation of $44.53 million per share for the previous trading session. After opening the day at $2.43 per share, volume surged to 339,863, moving forward from its daily average volume of 101,103 shares. Beta value for the Company stands at 0.92, indicating its risk level. The stock remained in the $2.23 to $2.48 price range during the session.
Company’s graphical value indicates these stories about the stocks: During the last 5 trades the stock jumped almost +23.48%. During the last one month it rose with the percentage of +36.05. Its year to date performance remained progressive +290%. Soligenix, Inc., a development stage biopharmaceutical company, engages in developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. The company focuses on two segments, BioTherapeutics and Vaccine/Biodefense.
Has SNGX Found The Bottom and Ready To Move Up? Find Out Here
Elite Pharmaceuticals Inc (OTCBB:ELTP) opened its shares at the price of $0.13 for the day, its closing price was $0.120 after losing -6.25% for the day. The company traded with the total volume of 2.97 million shares, while its average trading volume remained 3.33 million shares. The beta of ELTP stands at 2.27.
If we review the company’s graph to check its previous trends, we come to know these figures: During the last 5 trades the stock jumped almost +9.29%. During the last one month it rose with the percentage of +9.29. Along with these, its year to date performance remained progressive +50.19%. Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, principally engages in the research, development, and licensing of proprietary controlled-release drug delivery systems and products.
Has ELTP Found The Bottom And Ready To Gain Momentum? Find Out Here
THEDIRECTORY.COM INC (OTCMKTS:SEEK) percentage change reduced -11.11%, to close at $0.0008 with the total traded volume of 145.09 million shares, more than average volume of 17.85 million.
Company’s year to date performance remained optimistic with the rise of +300%. If we look at the last 6 months of trade, that is in the bullish zone with an increase of +300%.
The 52-week price range of the stock remained $0.0001 - $0.0022, while during last trade its minimum price was $0.0007 and it gained its highest price of $0.0012. TheDirectory.com, Inc operates as a diversified local Internet search company. The company owns and operates a network of locally targeted, category specific search destinations through its local business search engine, TheDirectory.com.
Why Should Investors Buy SEEK After the Recent Fall? Just Go Here and Find Out
Cannabis Science Inc (OTCMKTS:CBIS) remained among the day losers and traded with volume of 726,220 shares in the last session, as compared to average volume of 2.46 million shares.
CBIS was a loser in the 5 days activity and slipped about -1.74%. The one month performance of the stock was positive and it scored more than +12.16%.
Its day's lowest price was $0.05 and its hit its day's highest price at $0.05. CBIS’s total market capitalization is $32.11 million along with 710.42 million shares outstanding. Cannabis Science, Inc., a development stage company, engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products. It primarily focuses on developing medications to treat autism, blood pressure, cancer and cancer side effects, HIV, and other illnesses, including general health maintenance.
Will CBIS Get Buyers Even After The Recent Rally? Find Out Here
About OTC Stock Picks:
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)